Stockscreener 앱 받기
40.16
0.32%
-0.13
시장 영업 전:
40.84
0.68
+1.69%
전일 마감가:
$40.29
열려 있는:
$40.5
하루 거래량:
1.71M
Relative Volume:
1.08
시가총액:
$7.42B
수익:
$29.52M
순이익/손실:
$-567.06M
주가수익비율:
-10.97
EPS:
-3.66
순현금흐름:
$-551.11M
1주 성능:
+0.83%
1개월 성능:
-8.85%
6개월 성능:
-12.96%
1년 성능:
+49.13%
1일 변동 폭
$39.36
$40.59
1주일 범위
$39.36
$41.40
52주 변동 폭
$26.56
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
명칭
Revolution Medicines Inc
전화
415-766-3638
주소
700 SAGINAW DR, REDWOOD CITY, CA
RVMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
40.16 | 7.42B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-16 | 재확인 | Needham | Buy |
| 2024-07-12 | 개시 | Barclays | Overweight |
| 2024-07-08 | 개시 | Jefferies | Buy |
| 2024-04-12 | 재확인 | Needham | Buy |
| 2024-04-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-04 | 개시 | Wedbush | Outperform |
| 2023-11-16 | 개시 | Raymond James | Outperform |
| 2023-02-28 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-10-21 | 개시 | Oppenheimer | Outperform |
| 2022-05-20 | 개시 | BofA Securities | Neutral |
| 2022-03-01 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-08-12 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-05-18 | 개시 | Goldman | Buy |
| 2020-05-21 | 개시 | H.C. Wainwright | Buy |
| 2020-03-09 | 개시 | Cowen | Outperform |
| 2020-03-09 | 개시 | Guggenheim | Buy |
| 2020-03-09 | 개시 | JP Morgan | Neutral |
모두보기
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
Sandy Cove Advisors LLC Acquires Shares of 42,008 Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Down -7.83% in 4 Weeks, Here's Why Revolution Medicines (RVMD) Looks Ripe for a Turnaround - MSN
Is Revolution Medicines, Inc. (RVMD) the Best Russell 2000 Stock to Invest in According to Analysts? - Insider Monkey
Revolution Medicines' SWOT analysis: stock poised for growth amid clinical trials - MSN
Certain Restricted Stock Units of Revolution Medicines, Inc. are subject to a Lock-Up Agreement Ending on 18-JAN-2025. - Marketscreener.com
Revolution Medicines (RVMD) Loses -7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Revolution Medicines (NASDAQ:RVMD) Trading Down 4.6%Should You Sell? - MarketBeat
(RVMD) Trading Advice - Stock Traders Daily
Revolution Medicines, Inc. (RVMD): The Biotech Stock with Biggest Upside Potential - Insider Monkey
Revolution Medicines’ SWOT analysis: stock poised for growth amid clinical trials - Investing.com Nigeria
Stocks Generating Improved Relative Strength: Revolution Medicines - MSN
Revolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, UBS Group Analyst Says - Defense World
UBS Group Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock - MarketBeat
Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Principal Financial Group Inc. Trims Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - Defense World
Brokerages Set Revolution Medicines, Inc. (NASDAQ:RVMD) Price Target at $65.82 - Defense World
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Revolution Medicines (RVMD) Shares Cross Below 200 DMA - Nasdaq
Revolution Medicines Becomes Oversold (RVMD) - Nasdaq
(RVMD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Revolution Medicines divulges new GTPase KRAS, NRAS and HRAS inhibitors - BioWorld Online
Revolution Medicines COO Margaret Horn sells shares worth $196,553 - Investing.com India
Revolution Medicines CEO Mark Goldsmith sells $531,860 in stock By Investing.com - Investing.com Australia
Break Through Cancer and Revolution Medicines Collaborate to Study Biomarkers for RAS(ON) Inhibitor in - EIN News
Revolution Medicines CFO Jack Anders sells shares worth $119,639 By Investing.com - Investing.com Australia
Revolution Medicines general counsel sells $72,600 in stock - Investing.com India
Revolution Medicines CEO Mark Goldsmith sells $531,860 in stock - Investing.com India
Revolution Medicines COO Margaret Horn sells shares worth $196,553 By Investing.com - Investing.com Canada
Revolution Medicines, Inc. (NASDAQ:RVMD) COO Sells $196,536.60 in Stock - MarketBeat
Revolution Medicines CFO Jack Anders sells shares worth $119,639 - Investing.com
Insider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Insider Sells 11,714 Shares of Stock - MarketBeat
Jack Anders Sells 2,635 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) Stock - MarketBeat
Finance Watch: FOPO Surge Continues With Big Offerings From Revolution, NewAmsterdam - Citeline News & Insights
(RVMD) Technical Data - Stock Traders Daily
Revolution Medicines' SWOT analysis: RAS inhibitor stock shows promise amid clinical trials - Investing.com
Wilmington Savings Fund Society FSB Invests $801,000 in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Barclays PLC Buys 192,021 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
One Revolution Medicines Insider Raised Their Stake In The Previous Year - Yahoo Finance
State Street Corp Has $239.43 Million Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Verition Fund Management LLC Takes Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines (NASDAQ:RVMD) Shares Gap Up on Insider Buying Activity - Defense World
Revolution Medicines director Schroeder acquires $59.9m in stock By Investing.com - Investing.com Australia
Revolution Medicines director Schroeder acquires $59.9m in stock - Investing.com India
Revolution Medicines Inc (RVMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):